Puma Biotechnology

About Puma Biotechnology

Puma Biotechnology, Inc. is a development-stage biopharmaceutical company focused on the in-licensing and development of novel therapeutics for the treatment of cancer. The company primarily serves patients diagnosed with various forms of cancer, including breast cancer, particularly those with HER2-positive tumors. Operating within the oncology market, Puma Biotechnology's business model revolves around acquiring rights to promising drug candidates and advancing them through clinical trials to regulatory approval and commercialization. The company generates revenue through the sale of its approved drugs, such as Nerlynx (neratinib), which is used for extended adjuvant treatment of early-stage HER2-positive breast cancer. Puma Biotechnology also engages in partnerships and licensing agreements to expand its market reach and enhance its product pipeline.